Cytomegalovirus: The role of antibodies in advancing CMV diagnostics

The Native Antigen Company offers a comprehensive range of recombinant antigens and monoclonal antibodies for advancing cytomegalovirus (CMV) diagnostics and vaccine development. Featuring the newly developed recombinant human CMV glycoprotein B (gB) and PP65 antigens, along with six high-quality anti-CMV antibodies, these reagents provide superior sensitivity, specificity, and reproducibility. Ideal for use in ELISA, Western blot, immunofluorescence, and flow cytometry, these products enable reliable detection and immune response analysis in CMV research.